Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM.

Cancer Lett. 2011 Dec 8;311(2):219-29. doi: 10.1016/j.canlet.2011.07.023. Epub 2011 Aug 6.

2.

Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.

Ghadersohi A, Sharma S, Zhang S, Azrak RG, Wilding GE, Manjili MH, Li F.

Prostate. 2011 Aug 1;71(11):1178-88. doi: 10.1002/pros.21333. Epub 2011 Jan 12.

3.

Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.

Saifo MS, Rempinski DR Jr, Rustum YM, Azrak RG.

Mol Cancer. 2010 Dec 2;9:310. doi: 10.1186/1476-4598-9-310.

4.
5.

Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells.

Azrak RG, Frank CL, Ghadersohi A, Rustum YM.

Cancer Biol Ther. 2008 Dec;7(12):1901-8. Epub 2008 Dec 7.

PMID:
18981709
6.

Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.

Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F.

Int J Cancer. 2008 Sep 15;123(6):1376-84. doi: 10.1002/ijc.23667.

7.

Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF Jr, Prey J, Smith PF, Rustum YM.

Biochem Pharmacol. 2007 May 1;73(9):1280-7. Epub 2006 Dec 22.

8.

The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells.

Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM.

Mol Cancer Ther. 2006 Oct;5(10):2540-8.

10.

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM.

Clin Cancer Res. 2006 Feb 15;12(4):1237-44.

11.

Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.

Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM.

Mol Cancer Ther. 2005 May;4(5):843-54.

12.
13.

Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.

Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM.

Clin Cancer Res. 2004 Feb 1;10(3):1121-9.

14.

Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.

Yin MB, Hapke G, Wu J, Azrak RG, Frank C, Wrzosek C, Rustum YM.

Biochem Biophys Res Commun. 2002 Jul 12;295(2):435-44.

PMID:
12150968
15.
16.

Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.

Yin MB, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM.

Mol Pharmacol. 2000 Mar;57(3):453-9.

PMID:
10692484
17.
18.

Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells.

Guo B, Yin MB, Tóth K, Cao S, Azrak RG, Rustum YM.

Oncol Res. 1999;11(2):91-9.

PMID:
10489165

Supplemental Content

Loading ...
Support Center